Investigations of Escherichia coli ST131 and H30Rx subclone from clinical samples
Acta Microbiologica et Immunologica Hungarica · 2025
DOI: 10.1556/030.2025.02710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Microbiologica et Immunologica Hungarica, 2025. Verfasst von Elif Aydin und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1Disinfection Sterilization and Antisepsis Department, Kütahya Health Sciences University, 43000, Kutahya, Turkey. Hauptthemen laut MEDLINE: Escherichia coli, Escherichia coli Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Escherichia coli is a highly adaptable Gram-negative bacterium, commonly part of the gut microbiota in humans and animals, yet capable of causing severe extraintestinal infections. Among its lineages, Sequence Type 131 (ST131) has emerged as a globally disseminated, multidrug-resistant, high-risk clone with remarkable capacity for systemic infections. This study provides a comprehensive molecular epidemiological characterization of 160 clinical E. coli isolates, collected between 15.09.2021 and 28.02.2022, assessing antimicrobial resistance profiles, virulence gene carriage, phylogenetic group distribution, prevalence of ST131 and H30Rx subclone, and biofilm-forming capacity. Isolates were identified by conventional and automated methods, with molecular analyses performed via in-house PCR assays. Our results reveal a striking 69.38% prevalence of ST131, with 95.5% harboring virulence genes and 81.99% exhibiting biofilm formation. Notably, ST131-positive isolates demonstrated extensive resistance to multiple antimicrobial classes, including ESBL production, and were dominated by the H30Rx subclone. Specifically, 73.87% of ST131 isolates were ESBL-positive, fluoroquinolone resistance was observed in 81.37%, while aminoglycoside resistance rate remained very low. The H30Rx subclone was strongly associated with ESBL positivity and multidrug resistance. Moreover, integron carriage diversity and strong association with fimA virulence gene further highlight the adaptive versatility of this clone. Given that ST131 and its H30Rx subclone are recognized as global pandemic lineages associated with multidrug resistance and severe infections, their detection in our cohort emphasizes both the clinical relevance and the public health risk posed by these clones. Our findings underscore the urgent need for targeted surveillance and control strategies, offering novel epidemiological insights into the molecular diversity and clinical threat posed by E. coli ST131 in Turkey.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Disinfection Sterilization and Antisepsis Department, Kütahya Health Sciences University, 43000, Kutahya, Turkey.
- 2Department of Medical Microbiology, Faculty of Medicine, Ataturk University, 25240, Erzurum, Turkey.
- 3Department of Microbiology, Faculty of Veterinary Medicine, Ataturk University, 25240, Erzurum, Turkey.
- 4Vaccine Application and Development Center, Ataturk University, 25240, Erzurum, Turkey.
- 5Department of Medical Pharmacology, Faculty of Medicine, Bilecik Şeyh Edebali University, 11230, Bilecik, Turkey.
ORCID-Profile: Elif Aydin, Selahattin Celebi, Ozgur Celebi, Demet Celebi, Ali Taghizadehghalehjoughi
Zitieren
APA
Aydin, E., Celebi, S., Celebi, O., Celebi, D., & Taghizadehghalehjoughi, A. (2025). Investigations of Escherichia coli ST131 and H30Rx subclone from clinical samples. Acta Microbiologica et Immunologica Hungarica. https://doi.org/10.1556/030.2025.02710
Vancouver
Aydin E, Celebi S, Celebi O, Celebi D, Taghizadehghalehjoughi A. Investigations of Escherichia coli ST131 and H30Rx subclone from clinical samples. Acta Microbiologica et Immunologica Hungarica. 2025. doi:10.1556/030.2025.02710
BibTeX
@article{Aydin2025,
author = {Aydin, Elif and Celebi, Selahattin and Celebi, Ozgur and Celebi, Demet and Taghizadehghalehjoughi, Ali},
title = {Investigations of Escherichia coli ST131 and H30Rx subclone from clinical samples},
journal = {Acta Microbiologica et Immunologica Hungarica},
year = {2025},
doi = {10.1556/030.2025.02710}
}
EUVIMED